UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on

. In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates were ($0.53) for FY 2014, ($0.38) for 2015, breakeven for FY2016, $0.40 for FY2017, and $1.12 for FY 2018. However, these estimates should not be used as an indicator for the company going forward.” Corcept Therapeutics closed on Friday at $4.08.